Sibi Thomas, DO
Interventional Cardiology · Frisco, TXNPI 1720365406
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Medtronic at 32.1% of the total. 2025 is the largest year on record at $80,687, 7.5 times the $10,828 reported in 2019. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 664 payments — averaging $215.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$46K
- Boston Scientific$34K
- Philips North America LLC$28K
- Shockwave Medical, Inc$12K
- Abbott$9K
- Edwards Lifesciences$8K
- plus $7K from 38 others
Across 2 payments — averaging $13,375 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$27K
What the payments were for
- Consulting fees$26,47518%
- Speaking & faculty fees$71,91450%
- Travel & lodging$20,85315%
- Food & beverage$23,95417%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRangio$30,077
- (9148) ICE 3D$14,146
- (9520) IGT Devices Undivided$12,001
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$11,789
- AMPLATZER AMULET$2,119
- ONYX FRONTIER$2,015
- SAPIEN 3 Ultra RESILIA$1,745
- Emboshield NAV6 system$1,551
- CoreValve Evolut$1,487
- Omnilink Elite vascular stent system$1,355
- Watchman$1,183
- EXCLUDER AAA Endoprosthesis$1,139
- CROSSBOSS$741
- Mitra Clip system$634
- NAVITOR$488
- (6574) Coronary Other$430
- TRICLIP$395
- Impella$282
- WATCHMAN Access System$268
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$241
How this compares
$143,217 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $79,634 |
| EntrestoSacubitril/Valsartan | 39 | $53,098 |
| BrilintaTicagrelor | 69 | $46,745 |
| Repatha SureclickEvolocumab | 29 | $27,187 |
| Ranolazine ErRanolazine | 27 | $3,763 |
| ClopidogrelClopidogrel Bisulfate | 81 | $1,089 |
| Metoprolol Succinate | 71 | $937 |
| Nifedipine ErNifedipine | 14 | $729 |
| Rosuvastatin Calcium | 39 | $495 |
| Atorvastatin Calcium | 46 | $429 |
| Lisinopril | 44 | $423 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 32 | $391 |
| Pravastatin Sodium | 17 | $372 |
| Carvedilol | 18 | $330 |
| Spironolactone | 32 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $79,63481 claims |
| NovartisEntresto | $886 | $53,09839 claims |
| AstraZenecaBrilinta | $211 | $46,74569 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Frisco
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.